Study
Efficacy of multi-layered human iPS cell-derived cardiovascular cell sheets in a pacing-induced canine dilated cardiomyopathy model
In 11 dogs with pacing-induced dilated cardiomyopathy, an iPSC-derived cardiovascular cell sheet improved ejection fraction and cardiac output versus sham at four weeks.
Summary Can lab-grown human heart cells improve heart failure in dogs? Show / hide ↓
Researchers gave five dogs with heart failure a layered patch made from human induced pluripotent stem cells, or reprogrammed cells that can become heart-related cells. The patch contained heart muscle cells, blood-vessel cells, and support cells, and was placed on the heart during surgery. Six other dogs had sham surgery, meaning an operation without the patch. After four weeks, the treated dogs' pumping score, called ejection fraction, rose by 9.38 percentage points, compared with 1.90 points in the sham group. Their heart output also improved, but this was a small study with only 11 dogs.
What this means for you: This is early animal evidence, not proof that the treatment works or is safe in people. You can ignore claims that this study supports buying a cell therapy or that it reverses aging; longer studies and human trials are needed.
early evidenceYu Shimoyama and colleagues tested IHJ-301, a multilayered human induced-pluripotent-stem-cell-derived cardiovascular cell sheet, in a pacing-induced canine dilated cardiomyopathy model. The construct combined cardiomyocytes, endothelial cells, and stromal cells. Five dogs received epicardial implantation and six received sham surgery. Four weeks later, the change in left-ventricular ejection fraction was 9.38 ± 1.47 percentage points with IHJ-301 versus 1.90 ± 0.34 with sham (p<0.05). Fractional shortening, stroke volume, and cardiac output also favored the cell-sheet group. The model was designed to maintain depressed cardiac function without mortality, which makes treatment readout easier. This is a useful large-animal bridge study, but it is not a human trial and it says nothing about longevity. The sample is very small. Follow-up was four weeks after implantation. The paper does not establish long-term engraftment, arrhythmia risk, tumor risk, durability, or clinical benefit in people. The result supports continued translational testing of engineered cell sheets for heart failure. It does not justify clinic use or a generalized claim that iPSC therapies rejuvenate aging tissues.
We established a non-ischemic large-animal heart failure model that sustains depressed function for one month, enabling clear therapeutic readouts. IHJ-301 significantly improved multiple parameters of cardiac function, providing preclinical evidence that IHJ-301 could offer a promising therapeutic option for DCM.
Canine model with n=11 and four-week follow-up. No human efficacy data. Long-term engraftment, arrhythmia, tumorigenicity, durability, and manufacturing scalability remain unresolved.
Cited by
1 encyclopedia entries reference this study.